Xilio Therapeutics Announces Board and Executive Changes
Ticker: XLO · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1840233
Sentiment: neutral
Topics: executive-changes, board-changes, compensation
Related Tickers: XLO
TL;DR
Xilio Therapeutics shakes up leadership: Levitan out, Earp in as CMO, with new exec pay details.
AI Summary
On June 13, 2024, Xilio Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the company announced the departure of Dr. Richard S. Levitan from its Board of Directors and the appointment of Dr. David J. Earp as Chief Medical Officer. The filing also disclosed compensatory arrangements for certain officers.
Why It Matters
Changes in key leadership roles and executive compensation can signal shifts in company strategy and future performance, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in executive leadership and board composition can introduce uncertainty regarding future strategic direction and operational execution.
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Registrant
- Dr. Richard S. Levitan (person) — Departing Board Member
- Dr. David J. Earp (person) — Appointed Chief Medical Officer
- June 13, 2024 (date) — Report Date
FAQ
Who has departed from Xilio Therapeutics' Board of Directors?
Dr. Richard S. Levitan has departed from Xilio Therapeutics' Board of Directors.
Who has been appointed as the new Chief Medical Officer?
Dr. David J. Earp has been appointed as the new Chief Medical Officer.
What is the principal executive office address for Xilio Therapeutics?
The principal executive office is located at 828 Winter Street, Suite 300, Waltham, Massachusetts 02451.
What is the telephone number for Xilio Therapeutics?
The telephone number for Xilio Therapeutics is (857) 524-2466.
What is the filing date of this 8-K report?
The 8-K report was filed on June 13, 2024.
Filing Stats: 640 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2024-06-13 16:15:17
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share XLO Nasdaq Global Select
Filing Documents
- xlo-20240613x8k.htm (8-K) — 42KB
- 0001558370-24-009138.txt ( ) — 163KB
- xlo-20240613.xsd (EX-101.SCH) — 3KB
- xlo-20240613_lab.xml (EX-101.LAB) — 16KB
- xlo-20240613_pre.xml (EX-101.PRE) — 10KB
- xlo-20240613x8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XILIO THERAPEUTICS, INC. Date: June 13, 2024 By: /s/ Chris Frankenfield Chris Frankenfield Chief Operating Officer